Hybridoma producing monoclonal antibody f4 which specifically binds to

Abstract

A unique monoclonal antibody against P-glycoprotein. The monoclonal antibody is different than those previously described and has the surprising property of reacting to a soluble form of P-glycoprotein. The invention further includes a novel hybridoma cell line which produces the antibody. A preferred embodiment of the novel antibody has been designated F4 which is believed to react at or near an extracellular transmembrane loop of P-glycoprotein selected from the group consisting of the third and sixth extracellular loops. The invention further comprises a method for detecting the presence of P-glycoprotein comprising reacting a specimen containing P-glycoprotein with the novel monoclonal antibody and detecting the reaction to show that P-glycoprotein is present. The invention, in a preferred embodiment, comprises detecting the presence of drug resistant carcinoma cells, in the absence of biopsy, comprising removing extracellular fluids from a patient for use as a specimen, and determining the presence of P-glycoprotein in the specimen by reacting the specimen with the the novel monoclonal antibody to show that P-glycoprotein is present as an indicator of drug resistance. The extracellular fluid may be any suitable fluid which could contain P-glycoprotein as an indicator of drug resistance. Such fluids may for example be plasma, lymph excretions, and especially ascites taken from the area of a tumor site.